Aptose Biosciences (TSE:APS) Reaches New 52-Week Low at $0.90

Aptose Biosciences Inc. (TSE:APSGet Rating) (NASDAQ:APTO)’s share price hit a new 52-week low during mid-day trading on Friday . The company traded as low as C$0.90 and last traded at C$0.90, with a volume of 16937 shares traded. The stock had previously closed at C$0.93.

Analysts Set New Price Targets

Separately, Jonestrading reissued a “buy” rating and issued a C$5.00 target price on shares of Aptose Biosciences in a research report on Friday, June 3rd.

Aptose Biosciences Trading Down 4.3 %

The stock has a 50-day simple moving average of C$1.03 and a two-hundred day simple moving average of C$1.25. The company has a debt-to-equity ratio of 0.72, a quick ratio of 6.70 and a current ratio of 6.89. The firm has a market cap of C$82.14 million and a PE ratio of -1.02.

Aptose Biosciences (TSE:APSGet Rating) (NASDAQ:APTO) last issued its earnings results on Tuesday, August 2nd. The biotechnology company reported C($0.14) earnings per share for the quarter, topping analysts’ consensus estimates of C($0.17) by C$0.03. As a group, sell-side analysts anticipate that Aptose Biosciences Inc. will post -0.73 EPS for the current year.

About Aptose Biosciences

(Get Rating)

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.

Featured Stories

Receive News & Ratings for Aptose Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptose Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.